225 reports of this reaction
3.5% of all CEFADROXIL reports
#4 most reported adverse reaction
DYSPNOEA is the #4 most commonly reported adverse reaction for CEFADROXIL, manufactured by Aurobindo Pharma Limited. There are 225 FDA adverse event reports linking CEFADROXIL to DYSPNOEA. This represents approximately 3.5% of all 6,348 adverse event reports for this drug.
Patients taking CEFADROXIL who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among CEFADROXIL users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for CEFADROXIL:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 225 FDA reports for CEFADROXIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 3.5% of all adverse event reports for CEFADROXIL, making it a notable side effect.
If you experience dyspnoea while taking CEFADROXIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.